Neuren Pharmaceuticals Limited (NURPF)
NURPF Stock Price Chart
Explore Neuren Pharmaceuticals Limited interactive price chart. Choose custom timeframes to analyze NURPF price movements and trends.
NURPF Company Profile
Discover essential business fundamentals and corporate details for Neuren Pharmaceuticals Limited (NURPF) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
4 Nov 2009
Employees
—
Website
https://www.neurenpharma.comCEO
Jonathan Charles Pilcher ACA, BSc
Description
Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. Its lead product is trofinetide, which is in Phase III clinical trial for the treatment of Rett syndrome, as well as has completed Phase II clinical trial to treat Fragile X syndrome. The company also develops NNZ-2591, which has completed Phase I clinical trial for the treatment of Phelan-McDermid, Angelman, Pitt Hopkins, and Prader-Will syndromes. In addition, it provides development services; and holds loan funded shares. The company was incorporated in 2001 and is based in Camberwell, Australia.
NURPF Financial Timeline
Browse a chronological timeline of Neuren Pharmaceuticals Limited corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 25 Feb 2026
Earnings released on 6 Aug 2025
EPS came in at $0.03 falling short of the estimated $0.05 by -44.00%, while revenue for the quarter reached $18.40M , beating expectations by +0.67%.
Earnings released on 27 Feb 2025
EPS came in at $0.64 falling short of the estimated $0.64 by -0.94%, while revenue for the quarter reached $119.15M , beating expectations by +4.61%.
Earnings released on 27 Aug 2024
EPS came in at $0.04 falling short of the estimated $0.07 by -44.02%, while revenue for the quarter reached $16.22M , missing expectations by -20.64%.
Earnings released on 29 Feb 2024
EPS came in at $0.57 falling short of the estimated $0.67 by -15.10%, while revenue for the quarter reached $115.06M , beating expectations by +2.25%.
Earnings released on 30 Jun 2023
EPS came in at $0.24 surpassing the estimated $0.21 by +14.49%, while revenue for the quarter reached $41.79M , beating expectations by +0.40%.
Earnings released on 31 Dec 2022
EPS came in at $0.04 , while revenue for the quarter reached $9.95M , beating expectations by +5.01%.
Earnings released on 30 Jun 2022
EPS came in at -$0.04 , while revenue for the quarter reached $195.28K .
Earnings released on 31 Dec 2021
EPS came in at $0.00 , while revenue for the quarter reached $2.32M , beating expectations by +27.76%.
Earnings released on 30 Jun 2021
EPS came in at -$0.05 , while revenue for the quarter reached $175.68K .
Earnings released on 31 Dec 2020
EPS came in at -$0.03 , while revenue for the quarter reached $549.86K , missing expectations by -28.74%.
NURPF Stock Performance
Access detailed NURPF performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.